| Name | Title | Contact Details |
|---|
Graceway Pharmaceuticals is a Bristol, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Guardian Pharmacy Services, headquartered in Atlanta, Georgia, is the nation’s third largest institutional pharmacy company and one of the fastest growing privately held companies in the state of Georgia. Founded in 2004, Guardian and its partner pharmacies focus on providing exceptional client service and patient care to long-term care customers in assisted living communities, skilled nursing facilities, hospice and behavioral health group homes. Guardian Pharmacy Services` business model allows partner pharmacies to operate as independent local businesses tailoring their services to the needs of customers in their respective markets. We take our responsibility to our customers and their residents very seriously, and always strive to make sure that every prescription we fill and every service we execute receives our utmost care and attention. In the end, customers are the winners as pharmacies devote more attention to them while still meeting the many demands of any business. Guardian is 100% committed to fostering a sustainable business driven by our core values, conducting business according to the Golden Rule; treating each other, our customers and residents fairly and honestly.
Precision BioLogic is a Dartmouth, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.
Illyria Consulting Group is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.